Fig. 1.
Vaccination with recombinant gB, vIL-10, or both proteins elicited binding and neutralizing antibody responses. (A) Experimental design and timeline. Three groups of five RhCMV-uninfected macaques were immunized three times with modified recombinant vIL-10, modified recombinant gB, or both. (B) Neutralizing antibody responses to recombinant vIL-10 were assessed in macaques vaccinated with either vIL-10 alone or with both vIL-10 and gB. The assay was completed in duplicate. (C) Plasma samples were assessed for RhCMV-neutralizing antibody responses using a cell culture-based assay. NT50 antibody titers are shown. A panel of macaques chronically infected with RhCMV (CI; dark blue inverted triangles) from the CNPRC was identified by ELISA. These animals were also assessed for RhCMV-neutralizing antibodies; n = 5 for each vaccine treatment group, and n = 26 for the CI group. Symbols indicate individual macaques, the boxes indicate the group mean, and the error bars display SEM of the assay completed in triplicate. (D) Plasma samples were assessed for RhCMV binding antibodies to the vaccine strain by ELISA. The assay was completed in duplicate, and the lines display the median A450 for each group.